摘要
目的探讨山芪通降胶囊对慢性肾脏病(CKD)3-4期患者血清纤溶酶原激活物抑制剂-1(PAI-1)、成纤维细胞生长因子23(FGF23)、自噬相关蛋白7(Atg7)、微管相关蛋白1轻链3Ⅱ(LC3-Ⅱ)水平及肾功能的影响。方法选择慢性肾脏病3-4期患者84例,按随机数表法分为对照组与观察组,各42例。2组均给予基础治疗,对照组联合尿毒清颗粒治疗,观察组联合山芪通降胶囊治疗。2组均持续治疗8周。比较2组临床疗效结果,治疗前后中医证候积分、肾功能、血清PAI-1、FGF23、Atg7、LC3-Ⅱ水平,比较2组不良反应发生情况。结果观察组临床疗效总有效率(85.71%,36/42)高于对照组(66.67%,28/42)(P<0.05)。与治疗前比较,2组治疗后各项中医证候积分、血清尿素氮(BUN)、肌酐(Scr)、尿酸(UA)、24 h尿蛋白定量(24 UPro)、PAI-1、FGF23水平均降低(P<0.05),观察组低于对照组(P<0.05);肌酐清除率(Ccr)、血清Atg7、LC3-Ⅱ水平均升高(P<0.05),观察组高于对照组(P<0.05)。治疗期间,2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论山芪通降胶囊可显著缓解慢性肾脏病3-4期患者临床症状,改善患者PAI-1、FGF23及肾脏自噬水平,有效提高患者肾功能,进而提高临床疗效,且安全性良好。
Objective To explore the effects of Shanqi Tongjiang capsule on the levels of serum plasminogen activator inhibitor-1(PAI-1),fibroblast growth factor 23(FGF23),autophagy related protein 7(Atg7)and microtubule-associated protein 1 light chain 3-II(LC3-II),and renal function in patients with stage 3-4 chronic kidney disease(CKD).Methods A total of 84 patients with stage 3-4 CKD were selected and divided into the control group and the observation group according to random number table method,with 42 cases in each group.Both groups received basic treatment.The control group was treated with the combination of Uremic Clearance Granules,while the observation group was treated with the combination of Shanqi Tongjiang capsules.Both groups received continuous treatment for 8 weeks.The clinical efficacy of two groups,traditional Chinese medicine(TCM)syndrome scores,renal function,levels of serum PAI-1,FGF23,Atg7,and LC3-Ⅱbefore and after treatment were compared.The occurrence of adverse reacions between two groups was compared.Results The total effective rate in the observation group(85.71%,36/42)was higher than that in the control group(66.67%,28/42)(P<0.05).Compared with before treatment,after treatment the scores of various TCM syndromes,the levels of blood urea nitrogen(BUN),serum creatinine(Scr),urine acid(UA),24-hour urine protein quantification(24 UPro),serum PAI-1 and FGF23 in both groups decreased(P<0.05),and the observation group was lower than the control group(P<0.05);The levels of creatinine clearance rate(Ccr),serum Atg7 and LC3-Ⅱincreased,and the observation group was higher than the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between two groups during the treatment period(P>0.05).Conclusion Shanqi Tongjiang capsules can significantly alleviate the clinical symptoms of patients with stages 3-4 CKD,improve the levels of PAI-1 and FGF23,and renal autophagy of patients,all of which can effectively enhance renal function and improve clinical efficacy.This therapy has good safety.
作者
伊世华
王冰
黄芳
何冰冰
巩昭勇
隋淑梅
YI Shihua;WANG Bing;HUANG Fang;HE Bingbing;GONG Zhaoyong;SUI Shumei(The Third Department of Nephrology,Heilongjiang Academy of Traditional Chinese Medicine/Heilongjiang Provincial Hospital of Traditional Chinese Medicine,Harbin 150036,China;The First Department of Hepatobiliary Spleen and Stomach Diseases,Heilongjiang Academy of Traditional Chinese Medicine/Heilongjiang Provincial Hospital of Traditional Chinese Medicine,Harbin 150036,China)
出处
《长春中医药大学学报》
2025年第8期883-887,共5页
Journal of Changchun University of Chinese Medicine
基金
黑龙江省卫生健康委员会医药卫生科研课题(20222121011102)。
关键词
慢性肾脏病3-4期
山芪通降胶囊
中医证候
纤溶酶原激活物抑制剂-1
成纤维细胞生长因子23
自噬相关蛋白7
微管相关蛋白1轻链3Ⅱ
stages 3-4 chronic kidney disease
Shanqi Tongjiang capsule
traditional Chinese medicine syndromes
plasminogen activator inhibitor-1
fibroblast growth factor 23
autophagy related protein 7
microtubule associated protein 1 light chain 3Ⅱ
